In previous studies, we have shown TEG011 efficacy against HLA-A*24:02-expressing tumor cells in vitro and an extended in vivo safety profile, as well as peripheral persistence of TEG011, where long-term persistence of TEG associated with reduced probability for developing extramedullary solid tumor masses in vivo (34, 40). Here, HLA-A is linked to neoplasm.